INVO Bioscience Q2 2024 revenue surged 481% to $1.84M; adjusted EBITDA improved by $1.1M to $(0.5)M

INVO Fertility, Inc.

2024-Q2 EPS reported -$1.25 revenue$3,412,883

Revenue $1,836,597, up 481% YoY ($315,902); clinic revenue up 611% to $1,807,921.
Net loss remained $(2.2) million; total operating expenses rose to $3.7M, including $1.0M non-cash expense.
Adjusted EBITDA improved to $(0.5) million from $(1.6) million in Q2 2023.
All three fertility centers (Middleton, Atlanta, Birmingham) reported sequential revenue growth and are collectively profitable.
Merger with NAYA Biosciences (all-stock) still in discussions for further extension; $25K in transaction costs incurred in Q2.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.